Castle Biosciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $357.3M+7.6% YoYTTM through 30 Jun 2026
Net Income -$19.4M-206.4% YoYTTM through 30 Jun 2026
Free Cash Flow -$489KTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 69.0% |
| EBITDA Margin | -4.6% |
| Operating Margin | -12.4% |
| Net Margin | -5.4% |
Returns
-5.1%ROE
-4.2%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio6.04x
Net Debt-$299.1Mnet cash position
Cash & Equivalents$62.1M
Quality Metrics
Altman Z-Score7.46
Piotroski F-Score4 / 9
FCF Margin-0.1%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $344.2M
Diluted EPS-$0.64TTMFY2025: $-0.83
Dividend
No dividend
Capital Allocation
R&D Spend$55.4M
Capex Intensity12.1%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.